← Leaderboards
Jay P McLaughlin
University Of Washington
$8,345,553
Attributed
$19,480,638
Total exposure
13
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.1M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,480,638 · 13
By mechanism
R01$13,349,200 · 6
UG3$3,609,491 · 2
UH3$981,998 · 1
R33$921,907 · 1
R21$376,000 · 1
R03$242,042 · 2
Top collaborators
- Marc J Kaufman8 shared
- Chang-Guo Zhan7 shared
- Jun Zhu7 shared
- Adel Nefzi5 shared
- Susruta Majumdar4 shared
- Tao Che3 shared
- Nazira El-Hage3 shared
- Vsevolod Katritch3 shared
Most similar at University Of Washington
Same institution · by research overlap
- Katie A Witkiewitz$18,625,939
- Charles Chavkin$29,473,455
- Kevin R. Coffey$846,111
- Michael G McDonell$9,663,091
- Michael R Bruchas$23,108,955
Others in their field
Top investigators on “Brain”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Michael W Weiner · Northern California Institute Res &Educ$149,959,854
- David A Bennett · Rush University Medical Center$148,375,056
- David Heimbrook · Leidos Biomedical Research, Inc.$145,442,397
- Walter John Curran · Thomas Jefferson University$114,442,832
- Hongkui Zeng · Allen Institute$113,960,965
Research focus
BrainMediatingBehavioralIn VivoExposure ToIn VitroCellsSignal TransductionFunctional DisorderMouse ModelOpioidProteinsBehaviorNeuronsDosePharmaceutical PreparationsStructureRewardsHiv InfectionsSeriesHiv-1ReportingMorphineInfection
Grant awards (38)
Development of negative allosteric modulators at the mu opioid receptor$2,664,000
UG3 · FY2025 · DA
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1Tat and cocaine$728,575
R01 · FY2025 · DA
Impacts of morphine and HIV-Tat exposures and dimethylfumarate treatment on brain BDNF and mitochondrial and behavioral dysfunction.$665,637
R01 · FY2025 · DA · contact PI
Targeting the allosteric sodium site with novel probes for delta opioid receptor$656,556
R01 · FY2025 · DA
Function of astrocytes autophagy in brain homeostasis and opioid-induced maladaptive behavior and addiction, in the context of HIV$349,323
R01 · FY2025 · DA
Cyclic Peptides to Treat Cocaine Use Disorder$981,998
UH3 · FY2024 · NS
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$696,079
R01 · FY2024 · DA
Impacts of morphine and HIV-Tat exposures and dimethylfumarate treatment on brain BDNF and mitochondrial and behavioral dysfunction.$668,482
R01 · FY2024 · DA · contact PI
Targeting the allosteric sodium site with novel probes for delta opioid receptor$664,982
R01 · FY2024 · DA
Function of astrocytes autophagy in brain homeostasis and opioid-induced maladaptive behavior and addiction, in the context of HIV$349,424
R01 · FY2024 · DA
Cyclic Peptides to Treat Cocaine Use Disorder$945,491
UG3 · FY2023 · NS
Impacts of morphine and HIV-Tat exposures and dimethylfumarate treatment on brain BDNF and mitochondrial and behavioral dysfunction.$697,228
R01 · FY2023 · DA · contact PI
Targeting the allosteric sodium site with novel probes for delta opioid receptor$653,137
R01 · FY2023 · DA
Function of astrocytes autophagy in brain homeostasis and opioid-induced maladaptive behavior and addiction, in the context of HIV$360,823
R01 · FY2023 · DA
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,165
R01 · FY2022 · DA
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$297,085
R33 · FY2022 · DA
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,554
R01 · FY2021 · DA
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$304,664
R33 · FY2021 · DA
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,165
R01 · FY2020 · DA
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$316,935
R33 · FY2020 · DA
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$3,223
R33 · FY2020 · DA
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$515,554
R01 · FY2019 · DA
HIV Tat protein mediation of neurochemical changes and increased opioid reward$435,480
R01 · FY2019 · DA · contact PI
Molecular mechanisms: Dysregulation of monoamine transporters by HIV-1 Tat and cocaine$537,119
R01 · FY2018 · DA
HIV Tat protein mediation of neurochemical changes and increased opioid reward$435,480
R01 · FY2018 · DA · contact PI
Synthesis and in vitro and in vivo screening of fused and tethered heterocyclic peptidomimetics for the discovery of new analgesics with decreased side effects$376,000
R21 · FY2018 · DA
HIV Tat protein mediation of neurochemical changes and increased opioid reward$435,480
R01 · FY2017 · DA · contact PI
HIV Tat protein mediation of neurochemical changes and increased opioid reward$431,124
R01 · FY2016 · DA · contact PI
HIV Tat protein mediation of neurochemical changes and increased opioid reward$447,980
R01 · FY2015 · DA · contact PI
Tat mediation of HIV-associated mood disorders via functional deficits in brain$360,568
R01 · FY2015 · MH · contact PI
Tat mediation of HIV-associated mood disorders via functional deficits in brain$424,442
R01 · FY2014 · MH · contact PI
Tat mediation of HIV-associated mood disorders via functional deficits in brain$407,912
R01 · FY2013 · MH · contact PI
Tat mediation of HIV-associated mood disorders via functional deficits in brain$427,181
R01 · FY2012 · MH · contact PI
Tat mediation of HIV-associated mood disorders via functional deficits in brain$454,750
R01 · FY2011 · MH · contact PI
Endogenous Opioid Mechanisms Modulating Stress$9,105
R03 · FY2006 · DA · contact PI
Endogenous Opioid Mechanisms Modulating Stress$78,500
R03 · FY2005 · DA
Endogenous Opioid Mechanisms Modulating Stress$78,637
R03 · FY2004 · DA
Endogenous Opioid Mediation of Stress and Drug Reward$75,800
R03 · FY2003 · DA